$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership / The creatively structured deal adds Amylin’s GLP-1 franchise and other assets to the two pharmas’ diabetes portfolio. /
Biogen Idec To Collaborate With Isis On Treatment For Degenerative Muscle Disorder / The two companies build on an existing partnership in spinal muscular atrophy to address another muscle-wasting disease. For the second time, they’ve arranged an option deal, with milestones built in both before and after licensing.
Financings Of The Fortnight Ponders The Potential Of Mapping The Microbiome / Plus news on recent financial activity by Tesaro, Omeros, Neviah Genomics and Aegerion Pharmaceuticals.
How Bad Are Biomedical Innovation Problems? Metrics Needed To Know For Sure / Panel at Brookings Institution conference says there is no comprehensive measure and the issue is more complex than just tracking R&D spending and FDA approvals.
BioInvent To Cut Jobs By A Quarter Following Head-To-Head Clinical Trial Disappointment / Sweden's antibody platform company BioInvent moves quickly to reorganize following disappointing Phase IIb clinical results with a potential antithrombotic antibody.
Korea Approves DPP-4 Inhibitor From LG Life Sciences; China And India Next? / After winning Korea approval, LG is looking to launch its diabetes product in China and India in 2014, but it will have to compete with existing MNC products to gain market share.
